Enoyl-ACP reductase inhibitors - Debiopharm Group/Nobelex Biotech

Drug Profile

Enoyl-ACP reductase inhibitors - Debiopharm Group/Nobelex Biotech

Alternative Names: Debio-1453; Debio-1454; FabI inhibitors - Debiopharm Group/Nobelex Biotech; Narrow-spectrum antibiotics - Debiopharm Group/ Nobelex Biotech

Latest Information Update: 25 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Debiopharm Group; Nobelex Biotech
  • Class Small molecules
  • Mechanism of Action Enoyl-ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Gonorrhoea; Gram-negative infections; Helicobacter infections

Most Recent Events

  • 25 Oct 2016 Early research in Helicobacter infections in Switzerland (unspecified route) (Debiopharm Group pipeline, October 2016)
  • 26 Jun 2014 Early research in Gonorrhoea in Canada (unspecified route)
  • 26 Jun 2014 Early research in Gram-negative infections in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top